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H I G H L I G H T S
• Omission of adjuvant radiotherapy in patients with one intracapsular groin metastasis results in 1% isolated groin recurrence
• Neither size of the metastasis nor lymph node ratio had a significant impact on the risk of groin recurrence.
• Adjuvant radiotherapy is not recommended in patients with a single occult intracapsular lymph node metastasis.
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Objective. Most guidelines advise no adjuvant radiotherapy in vulvar squamous cell carcinoma and a single
occult intracapsular lymph node metastasis. However, several recent studies have questioned the validity of
this recommendation. The aim of this study was to analyze the groin recurrence rate in patients with a single
intracapsular positive lymph node treated without adjuvant radiotherapy.
Methods. Patients with a single clinically occult intracapsular lymph node metastasis, treated without adju-
vant radiotherapy, formed the basis for this study. Groin recurrences, and the risk of death, were analyzed in re-
lation to the size of the metastasis in the lymph node and the lymph node ratio. Data were analyzed using SPSS,
version 26.0 for Windows.
Results. After a median follow-up of 64months, one of 96 patients (1%) was diagnosedwith an isolated groin
recurrence and another two (2.1%)were diagnosedwith a combination of a local and a groin recurrence. The only
isolated groin recurrence occurred in a contralateral lymph node negative groin. Size of themetastasis and lymph
node ratio had no impact on the groin recurrence risk, nor on survival. The 5-year actuarial disease-specific
and overall survivals were 79% and 62.5% respectively. The 5-year actuarial groin recurrence-free survival was
97%.
Conclusion. Because of the low risk of groin recurrence and the excellent groin recurrence-free survival, we
recommend that adjuvant radiotherapy to the groin in patientswith vulvar squamous cell carcinoma and a single
occult intracapsular lymph nodemetastasis can be safely omitted to prevent unnecessary toxicity andmorbidity.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Vulvar cancer is a rare disease and mainly affects older women. A
steep increase is seen in the yearly incidence in the Netherlands, from
1-2/100.000 in women aged 50 to 60 years to 14 per 100.000 in
women over 80 years [1]. Regional metastases in the inguinal femoral
lymph nodes occur frequently and are related to pathological variables
such as depth of invasion, lymph vascular space invasion and tumor
size [2]. Only stage T1A tumors with a diameter 2 cm or less and a
depth of invasion 1mmor less have a negligible risk of lymph nodeme-
tastases [3]. Standard treatment for all other squamous cell cancers
(SCC) of the vulva consists of a radical local excision of the primary
tumor and either lymph node evaluation by sentinel lymph node
(SLN) biopsy or primary inguinal femoral lymphadenectomy (IFL) [4].
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When positive lymph node(s) are identified following IFL, there is
debate about the issue of when and how to give adjuvant radiotherapy.
A randomizedGynecologic OncologyGroup (GOG) study showed a ben-
efit for adjuvant radiotherapy, both in terms of inguinal recurrence rate
and survival, in patients who had adjuvant radiotherapy to the groins
and pelvis as compared to patients who had a pelvic node dissection
without radiotherapy [5]. In a subgroup analysis of this study, patients
with a single clinically occult positive lymph node displayed no benefit
from radiotherapy. A subsequent study from our institution confirmed
that patients with a single clinically occult intracapsular lymph node
metastasis had a low risk of groin recurrence [6].
The current ESGO guidelines [4] and most, but not all [7] other
guidelines, recommend adjuvant radiotherapy, except for patients
with one clinically occult and pathologically intracapsular lymph node
metastasis [8–11]. However, some recent publications have questioned
these recommendations andhave recommended adjuvant radiotherapy
for all patients with lymph nodemetastases, irrespective of the number
and/or pathological characteristics of these metastases [12–15].
The objective of this study was to analyze recurrence patterns and
survival of patients with a single intracapsular lymph node metastasis
who were treated without adjuvant radiotherapy.
2. Patients and methods
2.1. Patients
The files of consecutive patients with SCC of the vulva and positive
lymph nodes treated from 1987 till 2018, by a radical local excision of
the primary tumor and either a unilateral or bilateral IFL, were retro-
spectively reviewed. Patients were treated in three referral hospitals
in the Netherlands and one in Sydney, Australia (Amsterdam UMC,
The Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital,
Radboud UMC and the Royal Hospital for Women (RHW), Sydney).
Patients with a single, clinically occult, positive lymph node without
capsule breakthrough who were treated without adjuvant radiother-
apy were included in this study. Clinically occult was defined as no
palpably suspicious lymph nodes. In these hospitals, it was standard
policy not to recommend adjuvant radiotherapy to the inguinal re-
gion, nor other adjuvant treatments in patients with the above-
mentioned lymph node characteristics. Surgery was performed by
experienced gynecologic oncologists who each treated more than
10 patients with invasive vulvar cancer each year. The following clin-
ical and pathological data were retrieved from the files: age of the pa-
tient, FIGO 2009 stage, clinical diameter of the primary tumor (mm),
total number of removed lymph nodes, lymph node ratio ≤ 10 versus
> 10 (percentage of positive nodes in relation to the total number of
resected nodes (per groin)), extra-capsular spread and size of the
metastasis in the lymph node (< 5mm versus ≥ 5 mm). The data on
pathological variables were retrieved from the pathology reports. In
cases where data were missing, the original slides were reviewed
by an experienced gynecologic pathologist. All patients had a radical
local excision of the primary vulvar tumor and a bilateral or unilateral
IFL, either primarily or after detection of a single positive sentinel
node. A unilateral tumor was defined as a tumor with a medial mar-
gin positioned > 1 cm from an imaginary line drawn between the cli-
toris and anus. In one participating center (RHW, Sydney) it was
standard policy not to perform a contralateral inguinal femoral dis-
section if a single, clinically occult, intracapsular lymph node metas-
tasis was found in the ipsilateral groin in a strictly unilateral vulvar
tumor. In the other centers a bilateral groin dissection was standard
policy, but this was individualized in selected cases after counseling
of the patient. The study was approved by the appropriate Institu-
tional Review Board (IRB), and written informed consent was waived
by the IRB, because according to Dutch law, this is not obligated if de-
identified patient data are used, keeping in mind the rules of good
clinical practice. Approval was obtained from the relevant RHW
Ethics Committee for inclusion of their de-identified data in this
study.
2.2. Follow-up
All patients were followed-up at regular intervals of at least 3
months in the first two years and 6 monthly thereafter. Recurrences
were subdivided into local, groin or distant (including pelvic recur-
rences). Groin recurrences were analyzed both per patient and per
groin.
2.3. Statistics
Standard descriptive statistics were applied: absolute and relative
frequencies for categorical variables andmedian and range for continu-
ous variables. Fisher's exact test was employed to evaluate associations
between categorical variables. Estimates of overall survival (OS), and
disease-specific survival (DSS) were performed based on the Kaplan-
Meier product limit method. OS was defined as the time from primary
diagnosis to death from any cause. Survivors were censored on the
last day they were known to be alive. DSS was defined as the time
from primary diagnosis to death from vulvar cancer. Survivors were
censored on the last day theywere knownwithout disease. The survival
curves were compared using the log-rank test. A p value of < 0.05 was
considered statistically significant for all analyses. Statistical analyses
were performed in SPSS Statistics for Windows, version 26.0 (IBM
Corp., Armonk, NY, USA).
3. Results
From the four hospital databases, 96 patients with vulvar cancer and
a single clinically occult intracapsular lymph node metastasis were
identified. A bilateral (n=76) or unilateral (n=20) inguinal femoral
lymph node dissection, either primarily (n=64) or after a single posi-
tive sentinel node (n=32)was performed. The characteristics of the pa-
tients are shown in Table 1. In four patients, it was not possible to
retrieve the tumor diameter in the lymph node.
Of the 57 patients with a lymph node metastasis < 5mm, 26 metas-
tases had a diameter ≤ 2mm and three lymph nodes had only isolated
tumor cells. The median follow-up of censored patients was 64 months
(range 7-248). First recurrences occurred in 40 of 96 patients (41.7%)
after a median recurrence-free interval of 14 months (range 1-152).
One patient (1%) developed an isolated groin recurrence, and 2 pa-
tients (2.1%) developed a local and a groin recurrence. The only patient
with an isolated groin recurrence developed the groin recurrence in the
contralateral (right) groin nine months after a bilateral IFL with one
positive node out of 11 resected lymph nodes in the left groin and 0/9
in the right groin. Of the two patients with a combined local and groin
recurrence, one patient had a large local recurrence and a lymphangitis
carcinomatosa of the skin in the groin. The other patient had a local re-
currence and a groin nodal recurrence in the undissected left groin. This
patient initially had a single positive lymph node in the right groin (1
out of 6) and a negative sentinel node in the left groin.
Three patients developed an isolated pelvic recurrence. One patient
(33 years old) with a 10mmvulvar tumor and a 3mmnodalmetastasis
in the left groin had a 9 mm pelvic node in the left pelvis on a preoper-
ative CT scan. It was decided not to remove the pelvic node but 4
months postoperatively, the node had increased in size and was con-
firmed to be tumor positive by fine needle aspiration. Another patient
(77 years old) was treated for a 7 cm vulvar tumor by a radical local ex-
cision and a bilateral IFL. A single intracapsular nodal metastasis was
found,while pathology of the vulvar tumor showed tumor positivemar-
gins. This patient refused further radiotherapy and three months later
she was diagnosed with a left pelvic nodal recurrence. The third patient
(52 years old), with a 50 mm vulvar tumor and a 4 mmmetastasis in a
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left groin node, showed an isolated left pelvic recurrence 15 months
after the treatment of the primary tumor (Table 2).
The diameter of the metastasis in the node (< 5 mm vs ≥ 5 mm)
was not significantly associated with any groin recurrence (isolated
or combined): 1/57 (1.7%) vs 2/35 (5.7%) respectively (p = 0.322)
(S1). When a subdivision was made in diameter of the metastasis ≤
2 mm, 2-5 mm and ≥ 5 mm, again no significant difference in groin
recurrence rate was found (S2). Risk of groin recurrence (isolated
groin and combined groin) was not significantly different in the
group with a lymph node ratio ≤ 10 versus > 10: 2/54 (3.7%) versus
1/42 (2.4%) respectively (p = 0.594) (S3). The 5-year actuarial
disease-specific and overall survivals were 79% and 62.5% respec-
tively (Fig 1a/b). The 5-year actuarial groin recurrence-free survival
(including combined groin recurrences) was 97%. There was no sig-
nificant difference between the DSS or OS in the groups of patients
with size of the metastasis in the node < 5 mm versus ≥ 5 mm
(S4). The same was found for DSS and OS in the groups of patients
with a lymph node ratio ≤ 10 versus > 10 (S5).
4. Discussion
This study demonstrated a very low risk of an isolated groin recur-
rence in patients with squamous cell cancer of the vulva and a single
clinically occult intracapsular positive lymph node after IFL without ad-
juvant radiotherapy. Only one patient showed an isolated groin recur-
rence (on the contralateral side). Neither the size of the metastasis in
the lymph node (< 5 vs ≥ 5 mm) nor the lymph node ratio had any im-
pact on the groin recurrence rate and/or survival in this group of
patients.
Homesley and co-workers showed that therewas no benefit of adju-
vant radiotherapy in patients with one clinically occult positive lymph
node [5]. Although this was a subgroup analysis of a randomized con-
trolled trial and should have been hypothesis generating, many gyneco-
logic oncologists subsequently did not recommend adjuvant
radiotherapy for this specific group of patients. In a retrospective
study from the National Cancer Database, published in 1997, Creasman
and co-workerswere also unable to demonstrate any benefit from adju-
vant radiotherapy in patientswith a single positive lymph node. Neither
the size of themetastasis nor the presence of extra-capsular spreadwas
considered in this analysis [16].
As shown in Table 3, the policy of abandoning adjuvant radiotherapy
in patients with a single positive lymph node is recommended in most
published national guidelines [4,7–11]. Most of the national guidelines
take the number of nodes, presence of extra-capsular spread and the
size of themetastasis into consideration when recommending adjuvant
radiotherapy. Only the NCCN guidelines do not take extra-capsular
spread into account, recommending adjuvant radiotherapy in any pa-
tientwith positive inguinal femoral lymph nodes [7]. In the latter guide-
lines, the number of positive nodes and the size of the metastasis are
used to consider adding chemotherapy to the radiotherapy.
Despite these national recommendations, several recent studies
have questioned this policy [12–15,17–19]. A summary of the literature
on this subject is shown in Table 4. Six out of 10 published studies rec-
ommend adjuvant radiotherapy in all patients, irrespective of the num-
ber of positive lymph nodes [12–15,17,19]. Three other studies do not
recommend adjuvant radiotherapy [5,6,16], while the large AGO study
could not show a significant difference in recurrence free survival with
or without adjuvant radiotherapy and was therefore considered incon-
clusive [18]. The main flaws in the studies are that the previously men-
tioned nodal characteristics are not always considered. Clinically
suspicious nodes, large diameter nodal metastases and especially
extra-capsular spread are well known poor prognostic variables
[2,20,21]. Comparing adjuvant radiotherapy with no further treatment
in patients with a single positive node will only be scientifically valid
when the frequencies of these poor nodal characteristics are reported
and well balanced.
Two studies, expressing a preference for adjuvant radiotherapy for
all patients with positive lymph nodes take into account extra-
capsular spread [12,15]. In one of these studies, there is no specific infor-
mation on extra-capsular spread or recurrence pattern in the six re-
ported patients with a single nodal metastasis who did not get
adjuvant radiotherapy [12]. In the other study, Serre and co-workers
Table 1
Characteristics of clinical and pathological variables in 96 patients with a single positive
lymph node after complete IFL without RT. (* = percentage of positive nodes to the total
number of resected nodes per groin)
Variable
Age (median and range) 69 (33-96)
Clinical tumor size in mm (median and range) 30 (24-120)
















Size of nodal metastases in mm: mean ± SD
• < 5 mm

















• Local plus groin









Characteristics of the three patients with a groin recurrence and three patients with a pelvic recurrence
Age Initial treatment
groin(s)
Diameter of lymph node
metastasis (laterality)
Recurrence Time to recurrence
(months)
Outcome
58 Bilateral IFL 9 mm (left) Isolated node right groin 10 DOD
82 Unilateral IFL right 5 mm (right) Local and skin right groin 6 DOD
81 Unilateral IFL right/SLN left 4 mm (right) Local and node left groin 4 DOD
77 Bilateral IFL Unknown (left) Isolated node left pelvis 3 DOD
52 Unilateral IFL left 4 mm (left) Isolated node left pelvis 15 DOD
33 Bilateral IFL 3 mm (left) Isolated node left pelvis 4 DOD
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report on 65 patientswith a single intracapsularmetastasis [15]. It is not
clearwhat the indicationswere for adjuvant radiotherapy in 22 patients
or for omitting adjuvant radiotherapy in the other 43 patients. In a
univariate analysis, adjuvant radiotherapy did not impact on
recurrence-free or overall survival, while in a multivariate analysis, ad-
juvant radiotherapy was an independent favorable prognostic variable
for recurrence-free but not overall survival. Unfortunately, no informa-
tion on the groin recurrence rate or groin recurrence-free survival was
available for patients with a single intracapsular metastasis who either
had adjuvant radiotherapy or observation. Hence, it is impossible to de-
termine the impact of radiotherapy on the tumor control in the groin in
this study.
Fig. 1. a/b. Disease specific survival (a) and overall survival (b) of patients with vulvar cancer and a single occult intracapsular metastasis without adjuvant radiotherapy
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Other than the one isolated groin recurrence in our series, it could be
argued that the three isolated pelvic nodal recurrences could have been
prevented if adjuvant groin and pelvic radiotherapy had been given. A
pelvic node metastasis in patients with a single positive groin node is
very uncommon. Both Curry et al and Hacker et al reported no pelvic
nodal metastases in 16 patients with a single positive groin node
[22,23]. In contrast, and in line with our findings, one study reported
pelvic metastases in 2 of 14 such patients (14.3%) [5] and another in 1
of 44 (2.3%) [6]. This would give an overall incidence of 3.3% (3/90).
Whether adjuvant radiotherapy could have prevented these recur-
rences remains unproven, but it does suggest that preoperative imaging
(PET/CT scan) should be considered to try to exclude pelvic lymph node
metastases. Adjuvant groin and pelvic radiotherapy, even in patients
with a single occult groinmetastasis, does not always prevent pelvic re-
currences [5,6,24] and it increases the risk of lower limb lymphedema
after IFL [25,26]. Short term grade 1 and 2 morbidity will also increase,
even after intensity modulated radiation therapy [27].
The main flaw of the current study is its retrospective nature, which
could theoretically result in a selection bias. A possible selection of
prognostically favorable patients is unlikely, however, because the
local guidelines of the participating institutes advocate omitting adju-
vant radiotherapy in patientswith a single occult intracapsularmetasta-
sis. The strength of the study is the large number of patients from
institutes that perform a high volume of surgical procedures for vulvar
cancer. Additionally, all known relevant prognostic clinical and patho-
logical variables with respect to the lymph node metastases were
taken into account, such as clinical node status, the size of themetastasis
and extra-capsular spread.
In conclusion, among 96 patients with vulvar SCC and a single occult
intracapsular lymph node metastasis treated with IFL without adjuvant
radiotherapy, a 1% risk of isolated groin recurrence was seen. Therefore,
we suggest that adjuvant radiotherapy to the groin and pelvis should
not be recommended in these patients.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2020.10.008.
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